CUE
NASDAQ HealthcareCue Biopharma, Inc. - Common Stock
Biotechnology
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
๐ Market Data
| Price | $37.05 |
|---|---|
| Volume | 381,537 |
| Market Cap | 269.15M |
| Beta | 2.460 |
| RSI (14-Day) | 71.6 Overbought |
| 200-Day MA | $19.37 |
| 50-Day MA | $29.25 |
| 52-Week High | $45.50 |
| 52-Week Low | $4.98 |
| Forward P/E | -77.19 |
| Price / Book | 83.82 |
๐ฏ Investment Strategy Scores
CUE scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (95/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CUE in your text
Paste any article, transcript, or post โ the tool will extract CUE and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.